These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33866129)

  • 21. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
    Ibrahim MAA; Mohamed EAR; Abdelrahman AHM; Allemailem KS; Moustafa MF; Shawky AM; Mahzari A; Hakami AR; Abdeljawaad KAA; Atia MAM
    J Mol Graph Model; 2021 Jun; 105():107904. PubMed ID: 33798836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.
    Prakash A; Borkotoky S; Dubey VK
    J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
    Farhat N; Khan AU
    J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M
    Bharadwaj S; Lee KE; Dwivedi VD; Kang SG
    Life Sci; 2020 Sep; 257():118080. PubMed ID: 32653520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
    Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
    Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amentoflavone derivatives significantly act towards the main protease (3CL
    Dey D; Hossain R; Biswas P; Paul P; Islam MA; Ema TI; Gain BK; Hasan MM; Bibi S; Islam MT; Rahman MA; Kim B
    Mol Divers; 2023 Apr; 27(2):857-871. PubMed ID: 35639226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Ibrahim MAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
    Sharma S; Deep S
    J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repurposing immune boosting and anti-viral efficacy of
    Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
    J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.